3 documents found, page 1 of 1
Myocardial Performance Improvement After Iron Replacement in Heart Failure Pati...
Ramos, Raúl; Ras Jimenez, Maria Del Mar; Basalo Carbajales, María Del Carmen; Jovells Vaqué, Sílvia; GARCIA-PINILLA, JOSE MANUEL; Cobo-Marcos, MartaFunding Information: The IRON-PATH II study was sponsored by CSL Vifor with coordination by Bellvitge Biomedical Research Institute (IDIBELL). The sponsor did not participate in the design of this study nor data analysis. An independent data and safety monitoring committee reviewed the data every 6 months. This study was approved by the local ethics committees for clinical research at each participating center ...
Levosimendan efficacy and safety : 20 Years of SIMDAX in clinical use
Papp, Zoltán; Agostoni, Piergiuseppe; Alvarez, Julian; Bettex, Dominique; Bouchez, Stefan; Brito, Dulce; Cˇerný, Vladimir; Comin-Colet, JosepLevosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosp...
Influence of affective status on NT-proBNP levels in patients with chronic hear...
Badosa, Neus; Comin-Colet, Josep; Ruiz, Sonia; Rizzo, Marcelo; Ammirati, Adriano Luiz [UNIFESP]; Garcia-Bascunana, B.; Ivern, Consol; Bruguera, JorgeHosp del Mar, Dept Cardiol, Heart Failure Unit, Barcelona, Spain; Universidade Federal de São Paulo, Dept Clin Med, São Paulo, Brazil; Universidade Federal de São Paulo, Dept Clin Med, São Paulo, Brazil; Web of Science